Sensei Biotherapeutics shares jump 11.04% intraday after $200 million capital raise and key clinical milestones for PIKTOR.

Sensei Biotherapeutics surged 11.04% intraday following news of a $200 million capital infusion secured in February 2026 through a private placement, significantly strengthening its financial runway. The funding, which was not reflected in year-end 2025 figures, is tied to the acquisition of Faeth Therapeutics and is earmarked to support key clinical milestones for its lead candidate, PIKTOR. The company also reported a sharp reduction in net losses and operational expenses, signaling improved financial discipline. These developments, combined with the recent pricing of in-the-money stock options, have bolstered investor confidence in the firm’s near-term prospects and its ability to advance its oncology pipeline.